Does BioMarin (BMRN) Have the Potential to Rally 40.54% as Wall Street Analysts Expect?

Shares of BioMarin Pharmaceutical (BMRN) have gained 10.6% over the past four weeks to close the last trading session at $68.25, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$95.92 indicates a potential upside of 40.5%.The mean estimate comprises 25 short-term price targets with a standard deviation of $16.71. While the lowest estimate of$65 indicates a 4.8% decline from the ...